Glenmark Pharmaceuticals, USA has been granted final approval by the United States Food & Drug Administration (FDA) for the extended-cycle oral contraceptive, levonorgestrel/ethinyl estradiol tablets USP, 0.15 mg/0.03 mg, the AB-rated generic version of Seasonale by Teva Women’s Health.
[adsense:336x280:8701650588]
ACG Pharmapack – a member of ACG Worldwide – is proud to have received the prestigious WorldStar 2015 Award from World Packaging Organization for its innovative. ACG Pharmapack, a member of ACG Worldwide, has received the prestigious WorldStar 2015 Award from World Packaging Organization for its innovative product, NoMist. An anti-fog packaging film, NoMist bagged the Award in the pharma & medical category, after having won the IndiaStar (organized by the Indian Institute of Packaging) and AsiaStar (organized by the Asian Packaging Federation) awards. The award ceremony and cocktail reception was held in Milan, Italy.
Waters has introduced the Acquity Arc System, a quaternary liquid chromatograph that gives analytical laboratories running established LC methods a clear choice for replicating or improving their separations performance. The company intends to begin shipping the Acquity Arc system to customers by this month end.
Carna Biosciences, a leading provider of drug discovery supporting products and services, collaborate with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical companies of Johnson & Johnson, to develop and commercialize small molecule protein kinase inhibitor programmes.
The US Food and Drug Administration (FDA) has approved Novartis' Promacta (eltrombopag) for the treatment of children six years and older with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promacta was approved by the FDA in 2008 for use in adult patients with the same condition.
Philips India and Ion Beam Applications S.A. (IBA), a global leader in proton therapy for the treatment of cancer, signed an exclusive agreement to enhance access to proton therapy in India. The collaboration also enables both organizations to mutually leverage technologies and solutions. Two companies have already signed multiple country-specific collaboration agreements, each optimized for the local market needs.The alliance combines Philips’ expertise and innovative imaging techniques for strengths in proton therapy.
Jubilant Life Sciences, one of the leading players in nutrition market and the largest manufacturers of vitamin B3 (Niacin and Niacinamide) in the world, announced a price increase of 10 per cent for Niacinamide, with immediate effect, for non-contract customers and wherever existing contracts permit. Niacin and niacinamide are forms of vitamin B3 and used in various pharmaceutical products.
The Dadha Group launched NetMeds.com. Netmeds is the “first-to-market” offering a consolidated, Pan-Indian solution for the quick online purchase and ensured fast delivery of prescriptions medications. India’s first e-marketplace for pharma in the form of a portal which offers an impressive selection of both prescription drugs and non-prescription products (OTC) drugs, supplying over 25,000 stock keeping units (SKUs) across India from its first warehousing hub in Chennai. Prescription medication users will have opportunity to select their required medications from more than 260 drug categories for the chronic conditions, such as diabetes, hypertension and cholesterol control.
Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in manufacture and supply of APIs, generics, specialty pharmaceuticals and life science ingredients. It also provides services in contract manufacturing and drug discovery. US Food and Drug Administration (USFDA) upgraded Jubilant Hollisterstier's pharmaceutical sterile manufacturing facility in Spokane, Washington (USA) to the status of Voluntary Action Indicated (VAI). This upgradation by the USFDA from Official Action Indicated (OAI) to VAI is indicative of the cGMP status at the facility since receiving the warning letter in 2013.
Sun Pharma Advanced Research Company Ltd. (SPARC) has licensed out glaucoma medicine Xelpros (latanoprost BAK-free eye drops) to a subsidiary of Sun Pharma for the US market.
CLICK HERE TO SUBSCRIBE,
PHARMATUTOR's DAILY EMAILS
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
